) 2023년 06월 09일 -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale.
Bulk pooled CRISPR screening has been a valuable tool to understand gene function on a genome scale. Adding single cell resolution to pooled CRISPR screens pairs individual gene perturbations with rich whole transcriptome expression phenotypes. This approach has expanded the capabilities of pooled CRISPR screening to understand cell types of perturbed cells and quantify changes in gene expression, regulatory networks, signaling pathways, and other complex signatures. However, the applications and scale of these studies have been limited by the throughput and cost of droplet-based single cell RNA-seq technology.
CRISPR Detect brings the scale of existing Parse Evercode technology to single cell CRISPR screening by enabling users to pair perturbations and transcriptional profiles in up to one million cells in a single experiment. This scale will expand the applications of single cell CRISPR screening particularly in drug discovery where cost has limited their use to targeted validation studies.
“We are thrilled to provide CRISPR Detect to the single cell community,” states Charlie Roco, PhD, Chief Technology Officer of Parse Biosciences. “We are particularly excited about the responses from our early access customers around enabling genome scale screens and the potential to expand the usage of single cell CRISPR screening in drug discovery.”
Parse is also announcing the broad availability of UDIs (unique dual indexes) for all Evercode products. UDIs improve sequencing data quality and enable more Evercode sequencing libraries to be analyzed together.
CRISPR Detect and UDIs will be highlighted in an upcoming webinar on June 15 at 9:00 AM PT. For more information, visit https://parse.bio/3IFc8CR.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005007/en